Hormone relationships in breast cancer: The role of receptor-binding proteins

George A. Degenshein; Franco Ceccarelli; Norman D. Bloom; Ellis H. Tobin

doi:10.1016/S0011-3840(79)80014-3

Hormone relationships in breast cancer: The role of receptor-binding proteins

George A. Degenshein, Franco Ceccarelli, Norman D. Bloom, Ellis H. Tobin

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	CO1,2-59
Journal	Current Problems in Surgery
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/S0011-3840(79)80014-3
State	Published - Jun 1979

Access to Document

10.1016/S0011-3840(79)80014-3

Cite this

@article{e31c0fa0a1fc4ea8ba51107b65aae4e1,

title = "Hormone relationships in breast cancer: The role of receptor-binding proteins",

author = "Degenshein, {George A.} and Franco Ceccarelli and Bloom, {Norman D.} and Tobin, {Ellis H.}",

note = "Funding Information: This work was supported by the Jack R. Aron Research Foundation, the Ben Eisenstadt Research Fund, the Women's Division of Maimonides Medical Center and National Institutes of Health Grant 5S01RRo5497-B. 6 py was often used, but a depressing downhill course was the rule. In the last 2 decades the management of breast cancer, especially the advanced disease, has become truly multidisciplinary. The radiologist is making a new bid for primary treatment, and diagnostic mammography is widely used. The introduction of chemotherapy has provided another modality for treatment which is still under intense investigation. Since its effectiveness depends on toxicity, it needs time to establish its worth, especially in regard to life-style in responders. We are completing the full cycle of management concepts from conservative versus agressive chemotherapy to therapeutic chemotherapy versus adjuvant drug therapy. Although oncology has new drugs in its armamentarium and there is promise for newer ones, the place of chemotherapy is far from well defined. Although still groping in unchartered areas, the immunotherapist may soon add important modalities of prevention and treatment. The research worker is a contender with skin tests under study, examination of biochemical markers to identify high risks and with other sophisticated approaches to the cancer cell itself. The introduction of receptor protein studies represents one of the most important advances in the overall management of breast cancer since the introduction of the radical mastectomy. It promises to identify for us a group of hormone-dependent breast cancers that can respond to very specific modalities of treatment, such as hormone ablation or endocrine manipulation. ~ It also helps us to exclude those women who should not be treated by endocrine management because of the predictably high rate of failure. Receptor binding proteins represent a ray of light guiding us toward a better understanding of the biology of the tumor and may well lead us to a better knowledge of cancer. Tumors such as melanoma, renal cell carcinoma, endometrial carcinoma and others that may be hormone dependent are already under study. One of the most difficult judgments that the clinical surgeon must make is when to introduce data emerging from laboratory experiments into practical clinical application: It is the intent of this presentation to discuss the hormone relationships of breast cancer and describe the study of steroid-binding receptor proteins as a necessity for the rational management of this disease.",

year = "1979",

month = jun,

doi = "10.1016/S0011-3840(79)80014-3",

language = "English",

volume = "16",

pages = "CO1,2--59",

journal = "Current Problems in Surgery",

issn = "0011-3840",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Hormone relationships in breast cancer

T2 - The role of receptor-binding proteins

AU - Degenshein, George A.

AU - Ceccarelli, Franco

AU - Bloom, Norman D.

AU - Tobin, Ellis H.

N1 - Funding Information: This work was supported by the Jack R. Aron Research Foundation, the Ben Eisenstadt Research Fund, the Women's Division of Maimonides Medical Center and National Institutes of Health Grant 5S01RRo5497-B. 6 py was often used, but a depressing downhill course was the rule. In the last 2 decades the management of breast cancer, especially the advanced disease, has become truly multidisciplinary. The radiologist is making a new bid for primary treatment, and diagnostic mammography is widely used. The introduction of chemotherapy has provided another modality for treatment which is still under intense investigation. Since its effectiveness depends on toxicity, it needs time to establish its worth, especially in regard to life-style in responders. We are completing the full cycle of management concepts from conservative versus agressive chemotherapy to therapeutic chemotherapy versus adjuvant drug therapy. Although oncology has new drugs in its armamentarium and there is promise for newer ones, the place of chemotherapy is far from well defined. Although still groping in unchartered areas, the immunotherapist may soon add important modalities of prevention and treatment. The research worker is a contender with skin tests under study, examination of biochemical markers to identify high risks and with other sophisticated approaches to the cancer cell itself. The introduction of receptor protein studies represents one of the most important advances in the overall management of breast cancer since the introduction of the radical mastectomy. It promises to identify for us a group of hormone-dependent breast cancers that can respond to very specific modalities of treatment, such as hormone ablation or endocrine manipulation. ~ It also helps us to exclude those women who should not be treated by endocrine management because of the predictably high rate of failure. Receptor binding proteins represent a ray of light guiding us toward a better understanding of the biology of the tumor and may well lead us to a better knowledge of cancer. Tumors such as melanoma, renal cell carcinoma, endometrial carcinoma and others that may be hormone dependent are already under study. One of the most difficult judgments that the clinical surgeon must make is when to introduce data emerging from laboratory experiments into practical clinical application: It is the intent of this presentation to discuss the hormone relationships of breast cancer and describe the study of steroid-binding receptor proteins as a necessity for the rational management of this disease.

PY - 1979/6

Y1 - 1979/6

UR - http://www.scopus.com/inward/record.url?scp=0018775211&partnerID=8YFLogxK

U2 - 10.1016/S0011-3840(79)80014-3

DO - 10.1016/S0011-3840(79)80014-3

M3 - Review article

C2 - 467095

AN - SCOPUS:0018775211

SN - 0011-3840

VL - 16

SP - CO1,2-59

JO - Current Problems in Surgery

JF - Current Problems in Surgery

IS - 6

ER -